The Journal of the Arkansas Medical Society Med Journal Dec 2019 | Page 17

Thyroid Cancer in Arkansas: Facts & Figures
Figure 2: Figure
Age-Standardized
Thyroid
Incidence
95%
2: Age-Standardized
Thyroid Cancer
Cancer Incidence
Rates Rates
with 95 with
Percent
Confidence Intervals
by Intervals
Race and
Sex,
Arkansas,
2001-2015
Confidence
by Race
and
Sex, Arkansas,
2001 - 2015
12.7
14
12
8.6
10
According to the Arkansas Central Cancer
Registry (ACCR), beginning in 2001 through 2015,
there were 3,067 cases of papillary, 348 cases of
follicular, 89 cases of medullary, and 28 cases of
anaplastic thyroid cancer observed in Arkansas
(Arkansas Central Cancer Registry [ACCR], 2018).
Age, type, and stage of disease at the time of
diagnosis have been determined to be significant
prognostic factors of survivorship (Kebebew et al.,
4.9
6
2000 & Modigliani et al., 1998). The five-year rela-
2.5
4
tive survival rate for patients diagnosed with stage
I papillary or follicular thyroid cancer is approxi-
2
mately 100% (ACS, 2016). While the five-year rela-
0
tive survival rate for patients diagnosed with stage
Black, F
Black, M
White, F
White, M
I medullary thyroid cancer is also approximately
Note:
Incidence
rates rates
per 100,000
population;
age-adjusted
to the 2000
Standard
Note:
Incidence
per 100,000
population;
age-adjusted
to U.S.
the 2000
U.S. Population.
Standard Population.
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. National Program of 100%, the rate for those diagnosed at stage III or
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute.
Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: NPCR and SEER Incidence – U.S. Cancer Statistics 2001–
IV is 81% and 28%, respectively (ACS, 2016). All
Program
of Cancer
Registries
Surveillance,
Epidemiology,
End identified
Results based
SEER*Stat
Database:
NPCR and
2015 National
Public Use
Research
Database,
based on and
November
2017 submission.
Cases and
were
on “Site
and Morphology
Site Recode
ICD-O-3/WHO
2008 = –
Thyroid”.
Accessed
at www.cdc.gov/cancer/npcr/public-use.
on based
10/03/2018
SEER Incidence
U.S. Cancer
Statistics
2001–2015 Public Use Research Retrieved
Database,
on November 2017 submission.
cases of anaplastic carcinoma are considered to be
Cases were identified based on “Site and Morphology Site Recode ICD-O-3/WHO 2008 = Thyroid”. Accessed at www.cdc.
During the years Retrieved
2001-2015,
69.7% of the total cases among black males were diagnosed stage IV disease, and the five-year relative survival
gov/cancer/npcr/public-use.
on 10/03/2018
rate is approximately 7% (ACS, 2016).
8
at the early
stage
of disease,
and
the remaining 30.3%
of cases
diagnosed
in the
late four
stage
carcinoma
has were
the worst
prognosis
of the
The least
common
type of
undifferentiated
thyroid cancer is anaplastic (ACS, 2018). It is types of thyroid cancer (ACS, 2018). It is known Incidence
ACS featured Surveillance, Epidemiology, and
of an
disease
or were
Of the four
categories,
males life
were
to be race
the and
most sex
lethal
type, and white
the median
aggressive
and not
rare staged
type of (Figure
thyroid 3). cancer,
End Results Program (SEER) case projections in the
making up an estimated 2% of all thyroid can- expectancy after diagnosis is estimated to be
most likely diagnosed with late stage thyroid cancer; while black males fared worse in regards to 2018 publication of Cancer Facts & Figures, which
cers (ACS, 2018, NCI, 2018). Quick to metasta- four months (Gilliland et al., 1997 & Kebebew
> Continued on page 138.
et al., 2005).
size and followed
therefore by
difficult
treat, (Figure
anaplastic
unstaged,
white to
males
3).
We provide peace of mind
so you can, too.
Your Northwest Arkansas
Health Law Team
We’ve been addressing the legal needs of the Arkansas healthcare industry for almost 120 years.
• Medicare/Medicaid Reimbursement • Licensure Matters & Board Hearings
• Contracts & Business Transactions • Privileging & Peer Review
• Stark I and II & Anti-Kickback Compliance
• Government Regulations
• Operations & Management
• Medical Device & Pharmaceutical Products Defense
NUMBER 6
• Employment Issues
• HIPAA Compliance & Training
• Medical Malpractice Defense
Rogers
Little Rock
wlj.com
• Drug Diversion Prevention
DECEMBER 2019 • 137